Trial Profile
Adjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor bevacizumab (Avastin), as adjuvant therapy following resection of AJCC stage IIB (T4aN0M0) IIC (T4bN0M0) and III (TxN1-sM0) cutaneous melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms AVAST-M
- 13 Jul 2018 Primary endpoint (Overall survival rate) has not been met, according to results published in the Annals of Oncology.
- 13 Jul 2018 Primary endpoint (Overall survival) has not been met, according to results published in the Annals of Oncology.
- 13 Jul 2018 Results published in the Annals of Oncology.